Menu

Blog

Jun 28, 2022

New Drug Could Help Stop Depression, Anxiety, Brain Injury, and Cognitive Disorders

Posted by in categories: biotech/medical, neuroscience

The preclinical drug works by inhibiting the kinase Cdk5 which is found in mature neurons. Cdk5 has long been linked to neuropsychiatric and neurodegenerative disorders, but prior inhibitors have largely failed to cross the blood-brain barrier and enter the brain.

A new preclinical drug reported by James Bibb, Ph.D., and colleagues has the potential to combat depression, brain injury, and cognitive disorders. The drug, which is notable for being brain-permeable, works by inhibiting the kinase enzyme Cdk5.

Cdk5 is an important signaling regulator in brain neurons. Over three decades of research, it has been linked to neuropsychiatric and degenerative disorders such as Alzheimer’s.

Leave a reply